Kowa Company, Ltd. - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Kowa Company, Ltd. - Product Pipeline Review - 2016', provides an overview of the Kowa Company, Ltd.'s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Kowa Company, Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Kowa Company, Ltd. - The report provides overview of Kowa Company, Ltd. including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Kowa Company, Ltd.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Kowa Company, Ltd.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate Kowa Company, Ltd.'s strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Kowa Company, Ltd. - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Kowa Company, Ltd.'s pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Kowa Company, Ltd. Snapshot 6 Kowa Company, Ltd. Overview 6 Key Information 6 Key Facts 6 Kowa Company, Ltd. - Research and Development Overview 7 Key Therapeutic Areas 7 Kowa Company, Ltd. - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Partnered Products 12 Partnered Products/Combination Treatment Modalities 13 Kowa Company, Ltd. - Pipeline Products Glance 14 Kowa Company, Ltd. - Late Stage Pipeline Products 14 Pre-Registration Products/Combination Treatment Modalities 14 Phase III Products/Combination Treatment Modalities 15 Kowa Company, Ltd. - Clinical Stage Pipeline Products 16 Phase II Products/Combination Treatment Modalities 16 Phase I Products/Combination Treatment Modalities 17 Kowa Company, Ltd. - Early Stage Pipeline Products 18 Preclinical Products/Combination Treatment Modalities 18 Discovery Products/Combination Treatment Modalities 19 Kowa Company, Ltd. - Unknown Stage Pipeline Products 20 Unknown Products/Combination Treatment Modalities 20 Kowa Company, Ltd. - Drug Profiles 21 pemafibrate 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 anagliptin 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 peretinoin 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 K-134 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 ripasudil 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 epirubicin hydrochloride 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 K-312 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 pitavastatin NP 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Small Molecule to Agonize LXRB for Atherosclerosis 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Small Molecule to Inhibit Acyl-Coenzyme A for Undisclosed Indication 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Small Molecule for Oncology 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 K-163SZ 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Kowa Company, Ltd. - Pipeline Analysis 38 Kowa Company, Ltd. - Pipeline Products by Target 38 Kowa Company, Ltd. - Pipeline Products by Route of Administration 40 Kowa Company, Ltd. - Pipeline Products by Molecule Type 41 Kowa Company, Ltd. - Pipeline Products by Mechanism of Action 42 Kowa Company, Ltd. - Recent Pipeline Updates 44 Kowa Company, Ltd. - Dormant Projects 47 Kowa Company, Ltd. - Discontinued Pipeline Products 48 Discontinued Pipeline Product Profiles 48 pitavastatin CR 48 Kowa Company, Ltd. - Locations And Subsidiaries 49 Head Office 49 Other Locations & Subsidiaries 49 Appendix 52 Methodology 52 Coverage 52 Secondary Research 52 Primary Research 52 Expert Panel Validation 52 Contact Us 52 Disclaimer 53
List of Tables
Kowa Company, Ltd., Key Information 6 Kowa Company, Ltd., Key Facts 6 Kowa Company, Ltd. - Pipeline by Indication, 2016 9 Kowa Company, Ltd. - Pipeline by Stage of Development, 2016 10 Kowa Company, Ltd. - Monotherapy Products in Pipeline, 2016 11 Kowa Company, Ltd. - Partnered Products in Pipeline, 2016 12 Kowa Company, Ltd. - Partnered Products/ Combination Treatment Modalities, 2016 13 Kowa Company, Ltd. - Pre-Registration, 2016 14 Kowa Company, Ltd. - Phase III, 2016 15 Kowa Company, Ltd. - Phase II, 2016 16 Kowa Company, Ltd. - Phase I, 2016 17 Kowa Company, Ltd. - Preclinical, 2016 18 Kowa Company, Ltd. - Discovery, 2016 19 Kowa Company, Ltd. - Unknown, 2016 20 Kowa Company, Ltd. - Pipeline by Target, 2016 39 Kowa Company, Ltd. - Pipeline by Route of Administration, 2016 40 Kowa Company, Ltd. - Pipeline by Molecule Type, 2016 41 Kowa Company, Ltd. - Pipeline Products by Mechanism of Action, 2016 43 Kowa Company, Ltd. - Recent Pipeline Updates, 2016 44 Kowa Company, Ltd. - Dormant Developmental Projects,2016 47 Kowa Company, Ltd. - Discontinued Pipeline Products, 2016 48 Kowa Company, Ltd., Other Locations 49 Kowa Company, Ltd., Subsidiaries 50
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.